PRESS RELEASE - FEBRUARY 3, 2026

APMONIA THERAPEUTICS

Apmonia Therapeutics secures €10 million to advance first-in-human development of first-in-class cancer therapy TAX2

Press contact:

Acorelis Agency - Gilles Petitot:
+33 6 20 27 65 94 - gilles.petitot@acorelis.com

Apmonia Therapeutics:
contact@apmonia-therapeutics.com

Apmonia Therapeutics secures €10 million to advance first-in-human development of first-in-class cancer therapy TAX2

REIMS, France – February 3, 2026 - Apmonia Therapeutics ("Apmonia"), a biotechnology company developing next-generation cancer therapies targeting the tumor microenvironment, today announced that it has secured €10 million in financing. The financing is supported by Apmonia's existing investors Capital Grand-Est, FINOVAM Gestion, Fournier-Majoie Foundation, and Angels Santé, alongside new private investors and Capital Cell. The proceeds will be used to initiate Apmonia's first-in-human Phase 1/2a clinical study of TAX2 in patients with advanced solid tumors in France and Belgium, and to further expand Apmonia's proprietary extracellular matrix (ECM) platform to generate additional peptide-based therapeutic assets.

> ***"This financing is a pivotal step as we bring TAX2 into first-in-human development," said Albin Jeanne, Chief Executive Officer of Apmonia Therapeutics. "TAX2 is a first-in-class peptide new chemical entity (NCE) designed to selectively disrupt the TSP-1/CD47 interaction—an immune-suppressive mechanism embedded in the tumor microenvironment —while sparing the CD47–SIRPα pathway, thereby aiming to avoid the hematologic toxicities associated with systemic CD47 blockade. Our focus is now on executing a clinical program to the highest standards, generating meaningful patient data, validating this novel pathway in humans, and supporting partnering opportunities."***

Apmonia continues to expand its European footprint with a dedicated R&D subsidiary in Liège, Belgium, established in August 2025, and has strengthened its governance with the appointment of two independent Board members, Nissim Darvish, MD, PhD, and Julie Rachline, PhD.

TAX2 is designed to reprogram the tumor microenvironment

TAX2 is a cyclic 12–amino-acid peptide that selectively antagonizes the TSP-1/CD47 interaction. By preventing CD47 receptor activation mediated by tumor-overexpressed thrombospondin-1 (TSP-1), TAX2 is designed to act as a tumor microenvironment modulator, reprogramming highly vascularized tumors toward a less angiogenic state while restoring anti-tumor immune activity.

Apmonia has generated robust non-clinical proof-of-concept data supporting TAX2's immune-stimulatory and anti-tumor activity, including activation of tumor-specific T cells and significant tumor growth inhibition. TAX2's profile supports evaluation both as a monotherapy and in combination strategies, including immune checkpoint inhibitors and targeted therapies.

A multi-validated, groundbreaking scientific foundation

TAX2 is rooted in more than a decade of translational research on the extracellular matrix-driven TSP-1/CD47 axis, encompassing both Apmonia's proprietary research efforts and multiple independent academic research programs. This body of work, featured in leading peer-reviewed journals, supports the biological relevance of the pathway and the non-clinical efficacy of TAX2.

The phase 1/2a study is designed to validate TAX2 in patients and enable partnering

Apmonia will initiate a first-in-human, open-label Phase 1/2a study of TAX2 in patients with relapsed or refractory advanced or metastatic solid tumors. The study is designed to evaluate safety, tolerability, pharmacokinetics and pharmacodynamic biomarkers, while generating early clinical signals of activity—creating a clear value-inflection point to support partnering discussions with pharmaceutical companies.

Participating reference centers include Gustave Roussy (France), Centre Léon Bérard (France), Institut Jules Bordet (Belgium) and UZ Gent (Belgium).

A platform built to deliver multiple ECM-targeting assets

Beyond TAX2, Apmonia's proprietary discovery platform integrates advanced molecular modeling, AI-driven peptide design, and deep expertise in ECM biology to generate next-generation peptide-based therapeutics candidates designed to disrupt tumor–stroma interactions and overcome resistance mechanisms. The company is advancing follow-on oncology programs as well as earlier-stage discovery initiatives.

European expansion and governance strengthened

Apmonia's recent Board appointments bring complementary expertise aligned with the company's next phase of growth.

Nissim Darvish, MD, PhD, is a seasoned life-sciences investor and company builder, with experience spanning venture capital, biotech and medtech board leadership, and has been involved in multiple financings and strategic transactions, bringing deep know-how in scaling companies through key value-inflection points.

Julie Rachline, PhD, is an entrepreneur and life-sciences investment professional with extensive experience in building and positioning biotech and medtech equity stories; she has supported innovative health companies across strategy, clinical development, corporate execution, and investor relations.

Apmonia further increases its European footprint through clinical operations in Belgium and the establishment of its Liège-based R&D subsidiary dedicated to pipeline expansion.

About Apmonia Therapeutics:

Apmonia Therapeutics is advancing TAX2, a first-in-class peptide new chemical entity designed to selectively disrupt the TSP-1/CD47 interaction to restore anti-tumor immunity and inhibit tumor angiogenesis, while aiming to avoid the hematologic toxicities associated with systemic CD47 blockade. TAX2 is being developed for patients with advanced solid tumors and is designed for both monotherapy and combination strategies.

In parallel, Apmonia's proprietary ECM-targeting discovery platform leverages advanced molecular modeling, AI-driven peptide design, and deep expertise in extracellular matrix biology to generate additional peptide-based drug candidates designed to disrupt tumor–stroma interactions and overcome therapeutic resistance.

→ www.apmonia-therapeutics.com